Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial

F. Ciardiello, N. Normanno, E. Maiello, E. Martinelli, T. Troiani, S. Pisconti, F. Giuliani, C. Barone, G. Cartenì, A. M. Rachiglio, V. Montesarchio, G. Tonini, D. Rizzi, S. Cinieri, R. Bordonaro, A. Febbraro, F. de vita, M. Orditura, F. Fenizia, M. LambiaseA. Rinaldi, F. Tatangelo, G. Botti, G. Colucci

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Treatment with antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies has been restricted to metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors. Next-generation sequencing (NGS) allows the assessment in a single analysis of a large number of gene alterations and might provide important predictive and prognostic information. Patients and methods: In the CAPRI-GOIM trial, 340 KRAS exon 2 wild-type mCRC patients received first-line FOLFIRI plus cetuximab. Tumor samples (182/340, 53.5%) were assessed by NGS to search for mutations in 22 genes involved in colon cancer. Results: Objective responses in the NGS cohort were observed in 104/182 patients [overall response rate (ORR) 57.1%; 95% confidence interval (95% CI) 52% to 66.4%] with a median progression-free survival (mPFS) of 9.8 (95% CI 8.7-11.5) months. NGS analysis was successfully completed in all 182 samples. One or more genemutations (up to five) were detected in 124/182 (68.1%) tumors within 14/22 genes for a total of 206 mutations. KRAS exon 2 mutations were identified in 29/182 (15.9%) samples, defined as wild type by local laboratory assessment. Frequently mutated genes were: TP53 (39.6%), KRAS exons 3/4 (8.8%), NRAS exons 2/3 (7.1%), PIK3CA exons 9/20 (13.2%), BRAF (8.2%). FOLFIRI plus cetuximab treatment determined ORR of 62.0% (95% CI 55.5% to 74.6%) with mPFS of 11.1 (95% CI 9.2-12.8) months in patients with KRAS and NRAS wild-type tumors. Conversely, ORR was 46.6% (95% CI 39.9-57.5%) with mPFS of 8.9 (95% CI 7.4-9.6) months in patients with KRAS or NRAS mutations. Similarly, the subgroup of patients carrying KRAS, NRAS, BRAF, or PIK3CA mutations showed a worse outcome, although this might be due to a prognostic effect. Conclusions: This study demonstrates that NGS analysis in mCRC is feasible, reveals high level of intra and intertumor heterogeneity, and identifies patients that might benefit of FOLFIRI plus cetuximab treatment.

Original languageEnglish
Article numbermdu230
Pages (from-to)1756-1761
Number of pages6
JournalAnnals of Oncology
Volume25
Issue number9
DOIs
Publication statusPublished - 2014

Keywords

  • BRAF
  • Cetuximab
  • Colorectal cancer
  • KSA/NRAS
  • Next-generation sequencing
  • PIK3CA

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial'. Together they form a unique fingerprint.

Cite this